chd1l Antibody

What is CHD1L and why is it important to study using antibodies?

CHD1L (Chromodomain helicase/ATPase DNA-binding protein 1-like gene) is an oncogene that plays crucial roles in the progression of multiple solid tumors. Research has demonstrated that CHD1L is significantly upregulated in intrahepatic cholangiocarcinoma (ICC) tissues compared to adjacent non-tumor tissues . This upregulation correlates with poor clinical outcomes, including histological differentiation, vascular invasion, lymph node metastasis, and advanced TNM staging . Antibodies against CHD1L are essential research tools that enable detection and quantification of this protein in various experimental contexts, facilitating the investigation of its oncogenic functions and potential as a therapeutic target. The importance of reliable CHD1L antibodies is underscored by findings that CHD1L promotes tumor cell proliferation, metastasis, and G1/S cell cycle transition in cancer models .

Which tissue samples show the highest expression of CHD1L for antibody validation?

Based on current research, ICC tissues demonstrate significantly higher CHD1L expression compared to adjacent non-tumor tissues, making them excellent positive controls for antibody validation . In addition, highly aggressive ICC cell lines such as RBE and HUCCT1 exhibit notably elevated CHD1L protein levels compared to normal bile duct epithelial cell lines (HiBECs) . For developmental studies, testicular tissues from prepubertal and adult mice show substantial CHD1L expression, with specific colocalization with stem cell markers including PLZF, OCT4, and GFRα1 in neonatal mouse testes and undifferentiated spermatogonia . Researchers should consider these tissue types when validating new CHD1L antibodies or establishing positive controls for immunohistochemistry experiments.

What are the common applications for CHD1L antibodies in cancer research?

CHD1L antibodies are valuable tools in cancer research for several applications:

• Immunohistochemistry (IHC): Detecting CHD1L expression in paraffin-embedded tissue samples for correlation with clinical parameters and prognosis

• Western blotting: Quantifying CHD1L protein levels in cancer cell lines and tissue samples to assess expression differences

• Immunofluorescence: Examining CHD1L colocalization with other proteins to understand functional interactions

• Chromatin immunoprecipitation (ChIP): Investigating CHD1L binding to DNA and its role in transcriptional regulation

• Functional studies: Validating CHD1L knockdown or overexpression in cellular models before phenotypic assessment

In ICC research specifically, CHD1L antibodies have been instrumental in establishing the relationship between CHD1L expression and tumor aggressiveness, demonstrating significant associations with histological differentiation (P=0.011), vascular invasion (P=0.002), lymph node metastasis (P=0.008), and TNM stage (P=0.001) .

How can researchers optimize immunohistochemical detection of CHD1L in paraffin-embedded tissues?

Optimizing immunohistochemical detection of CHD1L in paraffin-embedded tissues requires careful attention to several parameters:

• Antigen retrieval: Based on published protocols, sodium citrate buffer (10 mM sodium citrate, pH 6.0) with 15 minutes of boiling has proven effective for unmasking CHD1L epitopes

• Blocking parameters: Use 3% hydrogen peroxide (10 minutes at room temperature) to block endogenous peroxidase activity, followed by 10% normal goat serum to reduce nonspecific binding

• Primary antibody incubation: Overnight incubation at 4°C with carefully titrated CHD1L antibody concentrations typically yields optimal results

• Detection system: HRP-conjugated secondary antibodies (goat anti-rabbit IgG) with 1-hour room temperature incubation provide reliable signal amplification

• Positive controls: Include ICC tissue sections or testicular tissues known to express CHD1L at high levels to validate staining specificity

For precise quantification of CHD1L expression by IHC, researchers should establish a standardized scoring system based on staining intensity and percentage of positive cells, as implemented in studies correlating CHD1L with clinical outcomes in ICC patients .

What are the critical considerations when designing knockdown experiments to validate CHD1L antibody specificity?

When designing knockdown experiments to validate CHD1L antibody specificity, researchers should address several critical considerations:

• Multiple shRNA constructs: Test several shRNA sequences targeting different regions of CHD1L mRNA, as demonstrated in studies using shCHD1L-1, shCHD1L-2, and shCHD1L-3, where shCHD1L-1 showed the most efficient knockdown

• Appropriate controls: Include both untransduced cells (CTRL) and non-targeting shRNA (shNC) controls to distinguish specific effects from technical artifacts

• Transduction efficiency verification: Confirm successful transduction using reporter genes (e.g., EGFP) and microscopy before proceeding with experiments

• Knockdown validation: Quantify knockdown efficiency at both mRNA level (by RT-qPCR) and protein level (by western blotting) before functional studies

• Phenotypic confirmation: Verify functional consequences of CHD1L knockdown through multiple assays (proliferation, colony formation, cell cycle analysis)

In published research, effective CHD1L knockdown in RBE and HUCCT1 cell lines was achieved using lentiviral vectors with transduction efficiencies exceeding 85%, resulting in significant reductions in both mRNA and protein expression levels .

How can researchers distinguish between specific and non-specific binding when using CHD1L antibodies in western blot applications?

Distinguishing between specific and non-specific binding when using CHD1L antibodies in western blot applications requires implementation of several validation strategies:

• Molecular weight verification: Confirm that the primary band appears at the expected molecular weight for CHD1L (~100 kDa), as observed in published western blots of ICC tissues and cell lines

• Positive and negative controls: Include samples with known high expression (e.g., RBE or HUCCT1 cells) and low expression (e.g., normal bile duct epithelial cells) of CHD1L

• Knockdown validation: Compare band intensity between samples with normal CHD1L expression and those with shRNA-mediated knockdown; specific bands should show significant reduction in knockdown samples

• Blocking peptide competition: Pre-incubate the antibody with a CHD1L-specific blocking peptide, which should eliminate specific bands while leaving non-specific signals unchanged

• Multiple antibodies: When possible, confirm results using antibodies targeting different epitopes of CHD1L

Additionally, careful optimization of blocking conditions (typically 5% non-fat milk or BSA) and antibody dilutions is essential to minimize background signals and enhance detection specificity.

What methods are most effective for studying CHD1L-induced EMT in cancer progression?

The epithelial-mesenchymal transition (EMT) induced by CHD1L plays a critical role in cancer invasion and metastasis. Based on current research, the following methods are most effective for studying CHD1L-induced EMT:

• Cell migration assays: Wound healing (scratch) assays effectively demonstrate CHD1L's impact on cell motility, with significant reductions in migration observed in CHD1L-depleted ICC cells (P<0.001)

• Invasion assays: Transwell Matrigel invasion assays quantitatively measure invasive capacity, revealing substantial decreases in CHD1L-knockdown cells compared to controls

• EMT marker analysis: Western blotting to detect changes in epithelial markers (E-cadherin) and mesenchymal markers (N-cadherin, vimentin) in response to CHD1L modulation

• Immunofluorescence microscopy: Visualizing subcellular localization and expression patterns of EMT markers after CHD1L knockdown or overexpression

• In vivo metastasis models: Xenograft models evaluating distant metastasis formation in response to CHD1L expression manipulation

Research has demonstrated that RBE and HUCCT1 cells with CHD1L knockdown express higher levels of E-cadherin and lower levels of N-cadherin and vimentin, confirming CHD1L's role in promoting EMT . Conversely, CHD1L overexpression in HCCC9810 cells increases mesenchymal markers while decreasing epithelial markers .

How can researchers accurately quantify CHD1L protein expression levels in clinical samples for prognostic studies?

Accurate quantification of CHD1L protein expression in clinical samples for prognostic studies requires a multi-faceted approach:

What controls are essential when studying CHD1L's role in cell cycle regulation using antibody-based techniques?

When investigating CHD1L's role in cell cycle regulation using antibody-based techniques, several essential controls must be implemented:

• Cell cycle synchronization controls:

  • Include both synchronized and unsynchronized cell populations

  • Verify synchronization efficiency using flow cytometry with propidium iodide staining

• Genetic manipulation controls:

  • Compare CHD1L-knockdown cells with both untransduced (CTRL) and non-targeting shRNA (shNC) controls

  • For overexpression studies, include empty vector-transfected cells (MOCK) as controls

• Cell cycle marker validation:

  • Confirm changes in cell cycle distribution using multiple methods (flow cytometry, EdU incorporation)

  • Validate cell cycle protein expression (p53, cyclin D1, CDK2) by western blotting in response to CHD1L modulation

• Functional validation controls:

  • Correlate cell cycle changes with functional assays (proliferation, colony formation)

  • Rescue experiments restoring CHD1L expression in knockdown cells to confirm specificity

Research has demonstrated that CHD1L knockdown increases G1 phase cells while decreasing S phase cells, with corresponding changes in p53 (upregulation), CDK2 and cyclin D1 (downregulation) . These findings should be replicated in any study examining CHD1L's cell cycle functions.

How can CHD1L antibodies be utilized in multiplex immunofluorescence to study its interactions with other proteins?

Multiplex immunofluorescence with CHD1L antibodies enables simultaneous visualization of CHD1L and its potential interacting partners or downstream effectors:

• Antibody selection considerations:

  • Choose antibodies raised in different host species to avoid cross-reactivity

  • Validate each antibody individually before multiplexing

  • Select fluorophores with minimal spectral overlap

• Optimization steps:

  • Determine optimal fixation methods preserving both CHD1L and partner protein epitopes

  • Establish appropriate blocking protocols to minimize background fluorescence

  • Test sequential versus simultaneous antibody incubation for optimal signal-to-noise ratio

• Advanced applications:

  • Colocalization analysis with transcription factors or chromatin regulators

  • Proximity ligation assays (PLA) to validate direct protein-protein interactions

  • Correlative studies with cell cycle markers (cyclin D1, CDK2) to understand temporal dynamics

Studies have successfully employed immunofluorescence to demonstrate CHD1L colocalization with stem cell markers (PLZF, OCT4, GFRα1) in testicular tissues and THY1+ undifferentiated spermatogonia , providing a foundation for similar approaches in cancer research.

What strategies should researchers employ to investigate CHD1L's chromatin remodeling functions using ChIP-seq?

Investigating CHD1L's chromatin remodeling functions through ChIP-seq requires careful experimental design and execution:

• Antibody qualification for ChIP:

  • Validate antibody specificity through western blotting and immunoprecipitation

  • Confirm efficient chromatin immunoprecipitation with pilot ChIP-qPCR experiments

  • Test multiple antibodies targeting different CHD1L epitopes to identify optimal performance

• Experimental design considerations:

  • Include appropriate controls (IgG, input DNA)

  • Perform biological replicates (minimum three) for statistical validity

  • Consider cell synchronization to capture cell cycle-specific binding patterns

• Data analysis approach:

  • Identify CHD1L binding sites genome-wide

  • Correlate binding sites with gene expression data from RNA-seq

  • Perform motif analysis to identify potential DNA binding preferences

  • Integrate with histone modification data to understand chromatin context

• Functional validation:

  • Confirm CHD1L binding at specific loci with ChIP-qPCR

  • Assess impact of CHD1L depletion on target gene expression

  • Investigate changes in chromatin accessibility at binding sites using ATAC-seq

This approach would extend current knowledge of CHD1L beyond its established roles in proliferation and EMT to comprehensively map its chromatin-dependent functions.

How can researchers address data inconsistencies when CHD1L antibodies show varying results across different experimental platforms?

Addressing inconsistencies when CHD1L antibodies yield varying results across experimental platforms requires systematic troubleshooting:

• Antibody characterization:

  • Verify antibody specificity using western blotting in multiple cell lines

  • Test multiple antibodies targeting different epitopes of CHD1L

  • Confirm batch consistency with lot-specific validation

• Protocol-specific optimization:

  • Adjust fixation and permeabilization conditions for each application

  • Optimize antigen retrieval methods for different sample types

  • Titrate antibody concentrations specifically for each platform

• Validation strategies:

  • Correlate protein detection with mRNA expression by RT-qPCR

  • Confirm antibody specificity using genetic approaches (knockdown/knockout)

  • Include positive controls with known CHD1L expression patterns

• Technical considerations for specific applications:

  • IHC: Test multiple antigen retrieval methods, including sodium citrate (pH 6.0)

  • Flow cytometry: Optimize fixation to preserve epitope accessibility

  • ChIP: Test different crosslinking conditions and sonication parameters

Researchers should document all variables systematically and consider publishing detailed methods papers to address the variability in CHD1L antibody performance across platforms.

How should researchers interpret the relationship between CHD1L expression and clinical outcomes in different cancer types?

Interpreting the relationship between CHD1L expression and clinical outcomes requires careful consideration of several factors:

This comprehensive approach provides context for interpreting CHD1L's prognostic significance across different malignancies.

What functional experiments are required to validate antibody-detected CHD1L expression patterns in novel research contexts?

Validating antibody-detected CHD1L expression patterns in novel research contexts requires a comprehensive suite of functional experiments:

• Genetic manipulation approaches:

  • RNAi-mediated silencing using multiple shRNA constructs targeting different regions of CHD1L mRNA

  • CRISPR/Cas9-mediated knockout for complete gene inactivation

  • Overexpression of CHD1L in low-expressing cell lines

• Proliferation and viability assays:

  • Cell counting kit-8 (CCK-8) assays to measure growth rates

  • Colony formation assays to assess clonogenic potential

  • In vivo tumor formation in nude mice to confirm oncogenic capacity

• Cell cycle and apoptosis analysis:

  • Flow cytometry to detect cell cycle distribution changes

  • BrdU incorporation to measure DNA synthesis

  • Apoptosis assays to assess cell death in response to CHD1L modulation

• Migration and invasion assessment:

  • Wound healing assays to quantify cell motility

  • Transwell migration and Matrigel invasion assays to measure invasive capacity

  • Analysis of EMT markers by western blotting

• Molecular pathway investigation:

  • Analysis of potential downstream targets (p53, cyclin D1, CDK2)

  • Assessment of signaling pathway activation (such as GDNF signaling in stem cells)

These functional experiments provide essential validation that observed CHD1L expression patterns are biologically meaningful in new research contexts.

What are the emerging applications of CHD1L antibodies in precision medicine and patient stratification?

CHD1L antibodies show promising potential for precision medicine applications based on current research findings:

• Prognostic biomarker development:

  • IHC-based detection of CHD1L in surgical specimens could identify ICC patients with higher risk of recurrence and poorer survival

  • Standardized scoring systems could enable patient stratification for adjuvant therapy decisions

• Therapeutic response prediction:

  • CHD1L expression levels may predict sensitivity to cell cycle-targeting agents, given its role in G1/S transition

  • Correlation of CHD1L with EMT status could identify patients likely to respond to anti-metastatic therapies

• Monitoring treatment efficacy:

  • Serial liquid biopsy analysis of circulating tumor cells (CTCs) using CHD1L antibodies could track treatment response

  • Changes in CHD1L expression during therapy might indicate developing resistance mechanisms

• Therapeutic target validation:

  • As a potential therapeutic target itself, CHD1L antibodies could help validate target engagement in early-phase clinical trials

  • Companion diagnostic development to identify patients suitable for CHD1L-targeting therapies

These applications represent promising future directions for translating CHD1L research findings into clinical practice, potentially improving outcomes for patients with CHD1L-overexpressing malignancies.

What methodological advances are needed to improve the reliability and reproducibility of CHD1L antibody-based research?

Several methodological advances would significantly enhance reliability and reproducibility in CHD1L antibody-based research:

• Antibody standardization:

  • Development of monoclonal antibodies with precisely mapped epitopes

  • Implementation of recombinant antibody technology for batch-to-batch consistency

  • Establishment of reference standards for antibody validation

• Reporting standards enhancement:

  • Comprehensive documentation of antibody characteristics (catalog number, lot, dilution, incubation conditions)

  • Detailed description of validation procedures performed

  • Inclusion of all appropriate controls in publications

• Protocol optimization:

  • Systematic comparison of fixation and antigen retrieval methods for different applications

  • Development of automated staining protocols to reduce technical variability

  • Creation of application-specific optimization guidelines

• Quantification improvements:

  • Implementation of digital pathology and automated image analysis for IHC quantification

  • Development of multiplexed approaches to simultaneously quantify CHD1L and related proteins

  • Standardization of scoring systems across research groups

These advances would address current challenges in reproducibility and facilitate more robust cross-study comparisons, ultimately accelerating the translation of CHD1L research findings to clinical applications.